Thursday, August 12, 2021 12:31:10 AM
KGROMAX QUOTE: "And as usual, Cytodyn and Salinimab will disappoint those that believe this pump, like everytime before"
I disagree vehemently.
CytoDyn's Leronlimab has been requested so much, and in such an overwhelming fashion that CytoDyn has had to stop accepting the flood of EINDs (Emergency Investigational New Drug applicatons for use).
And WHY would people go to such lengths, considering, the challenges in getting approval? Especially if the drug was as worthless as suggested above?
We have witnessed
Leronlimab do its thing and restored well-being to its recipients.
The following citations are a few examples of the positive effects of Leronlimab and how it's been successful in returning folks in dire situations, back to life. Take a look:
(Start the link below at the 40:00 mark)
https://content.production.cdn.art19.com/vali...Embers.mp3
https://www.sciencedirect.com/science/article/pii/S2589909021000034
https://www.thedickinsonpress.com/newsmd/coronavirus/7008927-Experimental-COVID-treatment-may-have-saved-ND-womans-life-doctor-says-more-study-needed
https://mb.com.ph/2021/04/19/ex-pres-erap-being-treated-with-leronlimab/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985604/
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277?login=true
https://nypost.com/2020/03/28/coronavirus-patients-taken-off-ventilators-after-getting-experimental-hiv-drug/
After noting the detractor's claims, check out the truth and decide for yourself!
And this listing doesn't include some of the posters on this board and their personal experiences with Leronlimab saving loved ones.
LERONLIMAB IS AMAZING STUFF - AND THE BRAZILIAN TRIALS SHOULD PROVE IT BEYOND ANY DOUBT.
I disagree vehemently.
CytoDyn's Leronlimab has been requested so much, and in such an overwhelming fashion that CytoDyn has had to stop accepting the flood of EINDs (Emergency Investigational New Drug applicatons for use).
And WHY would people go to such lengths, considering, the challenges in getting approval? Especially if the drug was as worthless as suggested above?
We have witnessed
Leronlimab do its thing and restored well-being to its recipients.
The following citations are a few examples of the positive effects of Leronlimab and how it's been successful in returning folks in dire situations, back to life. Take a look:
(Start the link below at the 40:00 mark)
https://content.production.cdn.art19.com/vali...Embers.mp3
https://www.sciencedirect.com/science/article/pii/S2589909021000034
https://www.thedickinsonpress.com/newsmd/coronavirus/7008927-Experimental-COVID-treatment-may-have-saved-ND-womans-life-doctor-says-more-study-needed
https://mb.com.ph/2021/04/19/ex-pres-erap-being-treated-with-leronlimab/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7985604/
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa1583/5932277?login=true
https://nypost.com/2020/03/28/coronavirus-patients-taken-off-ventilators-after-getting-experimental-hiv-drug/
After noting the detractor's claims, check out the truth and decide for yourself!
And this listing doesn't include some of the posters on this board and their personal experiences with Leronlimab saving loved ones.
LERONLIMAB IS AMAZING STUFF - AND THE BRAZILIAN TRIALS SHOULD PROVE IT BEYOND ANY DOUBT.
Recent CYDY News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/30/2026 08:32:50 PM
- CytoDyn Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer • GlobeNewswire Inc. • 04/27/2026 12:30:00 PM
- CytoDyn to Host Investor Webcast • GlobeNewswire Inc. • 04/23/2026 12:30:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 04/22/2026 09:21:50 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
